| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a5e95156255d5fe8b2923c544786e176 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2016-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cca354dfe821fe72f34b010943af8a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0c2dd01074cfed96ddaaff9e348fbba |
| publicationDate |
2017-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017056430-A1 |
| titleOfInvention |
Methods and Compositions for Treating Cancers and Enhancing Therapeutic Immunity by Selectively Reducing Immunomodulatory M2 Monocytes |
| abstract |
The present disclosure provides pharmaceutical compositions comprising nucleic acids capable of targeting IGF-1R expression in M2 cells. The present disclosure also provides methods for the selective reduction of M2 cells by targeting expression of IGF-1R in these cells. The present disclosure further provides methods for treating cancer and enhancing therapeutic by targeting expression of IGF-1R in M2 cells in patients. The pharmaceutical composition of the present invention is effective when administered systemically to subjects in need thereof. The ease of administration of the pharmaceutical composition facilitates treatment and enhances patient compliance. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10772904-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111447922-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2766457-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10206942-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018195281-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10265339-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020517631-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020517645-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018165528-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110650727-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11389475-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018195250-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10357509-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019147817-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3612162-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3628003-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10543226-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110832068-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019014511-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11077133-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7186721-B2 |
| priorityDate |
2015-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |